Answers are grounded in this paper and cite their sources.
For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR. This survival benefit must be balanced against the risk of neurological morbidity, which does increase with more aggressive cytoreduction, but only in the early postoperative period. Interestingly, this putative EOR threshold closely approximates that reported for newly diagnosed glioblastomas, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression.
No takes yet. Share an insight, caveat, or question.
Oppenlander et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: